

**Original Review Article**

DOI: 10.26479/2018.0405.22

GENETICS OF EUNUCHS: A REVIEWT N Chauhan^{1*}, RK Patel², J V Suthar¹, S M Dave³, M Patel³

1. Genetics Group of Gujarat Diagnostic Centre, Mehsana, Gujarat, India.

2. Sandor Animal Biogenics Pvt. Ltd., Hyderabad, Telangana, India.

ABSTRACT: Eunuchs are the people who are uncategorized sex, or more specifically a male to female psychosexual. Estimated 5 to 6 million *hijra*'s lived in India. In most cases they remain infertile due to genetic mutations during genital development. Several genes *SOX9*, *DAX1*, *WT1*, *WNT4* and *FGF9* are autosomal genes involve in sex determination and development. *SRY* gene is a candidate gene involve in sex determination which is located on Y chromosome. Mutation in any of these genes involve in sex differentiations can cause an abnormal genital development. These conditions are commonly called as Disorders of the Sex Development (DSD). Present article describes involvement of the genes in sex development and causes of DSD in eunuchs.

KEYWORDS: Eunuch, DSD, Sex determination, *SRY*, disorders of sex differentiation, genes involve in sex differentiation.

Corresponding Author: Dr. Tushar N Chauhan* Ph.D.

Genetics Group of Gujarat Diagnostic Centre, Mehsana, Gujarat, India.

Email Address: tusharchauhan3020@gmail.com

1. INTRODUCTION

The English word eunuch is derived from the Greek *eune* (bed) and *ekhein* (to keep), precisely "bed keeper". However, popularly, eunuchs are known as *hijra* / *hijda* in Hindi. Eunuchs are the people who are with uncategorized sex, or more specifically a male to female psychosexual [1] [2]. They are males, but having a female like abnormal external structure and behavior, estimated to be 5 to 6 million *hijras* lived in India [2]. Since their gender is not specified, eunuchs are categorized into third gender. Though, it is a psychosexual problem, but in almost 90% of cases the problem is originated due to clinical or genetic abnormalities [2]. Decreased production of male sex hormones, abnormal sex organs or abnormal gonad developments are major clinical causes in eunuchs.

© 2018 Life Science Informatics Publication All rights reserved

Peer review under responsibility of Life Science Informatics Publications

2018 Sept – Oct RJLBPCS 4(5) Page No.269

Chromosomal imbalance, deletion, translocation and sex reverse are genetic factors that might responsibly for gender identity disorders. In India, eunuchs lived a taboo life as they are not accepted in the society and therefore their medical and genetic status is restricted. The present article describes involvement of genetics in gender identity disorder, specifically in the male. Chromosomal anomalies and gene mutation play a major role in interruption of sex determination. Sex development can be divided into two categories; sex determination and sexual differentiation.

SEX DETERMINATION

Sex determination is defined as the developmental decision that directs the bipotential gonad to develop as a testis or an ovary. In mammals, sex determination is genetically controlled depending on a developmental time and gene expression. After the discovery of the sex determining region of chromosome Y (*SRY*) in 1990, research efforts have led to the identification master gene of *SRY* region. *SOX9*, *DAX1*, *WT1*, *WNT4* and *FGF9* are autosomal genes involve in sex determination and genital development [3]. Azoospermia, abnormal external genitalia, hypospadias and gyaenamomastis are several common problems related to sex determination. These disorders related to sex determination are commonly called as disorders of sex development (DSD).The sex of an individual is the unique identity of his or her own on earth. How the sex is determined is still a question for scientists. In mammals a complex genetic mechanism and an outer environmental influence, decides the sex of the fetus. Since the discovery of the Y chromosome, researchers got some direction about the sexual differentiation pathway. Interestingly, after discovery of *SRY* gene in 1990, the mechanism became more clearly defined.

SEX DIFFERENTIATION

At early embryonic stage gonads remain undifferentiated; during this stage the fetus is phenotypically female because all the sexes are same in fetus. After 6 to 7 weeks, development of testis begins under the influences of Y-chromosome. Sex differentiation is governed by meiosis by which the genetic basis of sex differentiation is determined. Meiosis is a process in which chromosomes are separated and individual sperm or egg is formed. At later stage it fertilizes to form a zygote [4]. The bipotential gonad is the stage wherein the genital ridge is formed resulting in either testis or ovary formation. Urogenital system is developed from genital ridge or gonadal ridge [5].

Table 1: embryonic development stages during sex differentiation

Age of conception	Event
32 Days	Gonadal primordia developed, Growth of Wolffian duct, Primordial germ cell differentiation
37Days	Primordial germ cells reaches gonad ridge, Differentiation of Müllerian ducts
42-50 Days	Somniferous cord differentiation
55-60 Days	Beginning of secretion of AMH, Leyden cell differentiation, Cranial part of Müllerian ducts begins to regress
9 th Week	Leydig cells produce testosterone. Beginning of masculinization of urogenital sinus and external genitalia
10 th - 12 th Week	The vaginal cord is formed Primordial follicles appear Seminal vesicles developed
14 th Week	Completion of male urethral organogenesis

Bipotential gonad & embryogenesis

Cells present in genital ridge, or bipotential gonad having capacity to develop in either male or female fate. This types of cell are common in both [6]. During the first 6 weeks of embryonic development the gonadal ridge, germ cells, internal ducts, and genitalia are bipotential in both 46,XX and 46,XY embryos.




Fig 1: Pathway of genes involve in human sex determination.

As shown in fig.1, the bipotential gonad represents the leydig cells and sertoli cells. As the *SRY* expressed, leydig cells undergo development of wolffian duct and finally to male sex. Whereas, sertoli cells produces the anti-mullerian hormones which inhibit formation of mullerian duct [7]. During the developmental stages genes as like *SRY*, *SOX9*, *SF1*, *WT1*, *GATA4*, *DMRT1*, *FOG2*, *WT4* and *EMX2* play an important role to determine sex. Bipotential gonadal ridge is located medially on the urogenital ridge which can be detected by 5 weeks of gestation (7). Male sex and reproductive organs like epididymis, vast deference and seminal vehicles are developed from the wolffian duct system, if all the necessary conditions are fulfill. In contrast female reproductive organs are developed from the mullerian duct system, i.e fallopian tube, uterus and vagina [6].

GENES INVOLVE IN SEX DETERMINATION

***NR0B1* nuclear receptor subfamily 0, group B, member 1**

NR0B1 located on X chromosome, situated at Xp21.2 [8]. *DAX1* is a nuclear receptor protein encoded by *NR0B1* gene, hence mutations in *NR0B1* is also referred as a *DAX1* mutation. *NR0B1* specifically expressed in adrenal gland, gonads, hypothalamus and pituitary gland. At the time of testicular development and before the expression of *SRY*, *NR0B1* is expressed in somatic cells. Hence, despite the presence of *SRY*, it can causes female development with increased expression of *NR0B1*. It is believed to be involved in ovarian development and so called as an anti- testis gene [6]. Duplication in *NR0B1* leads to DSD in female while deletion leads to congenital adrenal hypoplasia in male [9]. Anti-testis function of this gene is yet not conformed but the gonad differentiation is based on dosage sensitivity of *DAX1* therefore it is called as dosage sensitive gene which leads to female development in normal conditions[6]. The condition is initially referred as dosage sensitive sex reversal.

***WT1* (Wilms tumor suppressor 1)**

WT1 is located on chromosome number 11, mapped on 11p13 region which is expressed during genital development. It is a type of transcriptional factor with zinc finger protein. *WT1* has wide spectrum of expression with different isoforms, 2 well known isoforms are +KTS and -KTS. During gonad development +KTS isoforms increases stability of *SRY* whereas, -KTS binds to *SRY* [10]. Major expression site for *WT1* are coelomic epithelia cells, In contrast with other genes, *WT1* may not be a major clinical concern for DSD. Deletion or duplication of this gene is associated with complex phenotypic conditions. Wilms's tumor, aniridia, Denys-Drash syndrome, and Frasier syndrome [11], all of which share features of genitourinary abnormalities, particularly XY gonadal dysgenesis [9]. Notably *WT1* is associated with wide range of disorders but majorly it is involve with developmental disorders.

***NR5A1* (Nuclear Receptor subfamily 5, group A, member 1)**

It is called as nuclear receptor subfamily 5, group A, member 1, which regulates the expression of other genes. Generally *NR5A1* works further with other transcriptional factors. During

embryogenesis it expressed in urinogenital ridge, hypothalamus and anterior pituitary gland [6] and promotes or involves in regulating expression of AMH (anti-mullerian hormone) and *SOX9*. The 13% of NR5A1 mutations is directly involve in 46 XY DSD [12]. Experiments on mice were clearly suggest that lacking of *SFI* develops mullerian duct, while mutant *SFI* gene, fails to develop adrenal and male gonad [12].

Master gene SRY (Sex determine region on the chromosome Y)

Historically it was believed that sex of mammals was decided by Y chromosome. The factor present on Y chromosome is called as Testis Determining Factor; *TDF* [3] [13]. A region of 35kb located on the short arm of Human Y chromosome is responsible for sex determination and gene which is located within this *TDF* region is called as *SRY* [3][14][15]

Structure of SRY gene




Fig 2: structure of mice and human SRY gene located on Y chromosome.

SRY gene is located on distal, short arm of Y chromosome. As shown in figure.2, it has C terminus and N terminus ends, between both regions, high mobility group (HMG) box is present. This group of genes are known as *SOX* (*SRY* related high mobility group) family [3]. HMG box contains 79 amino acids and interact with (A/T) ACAA (T/A) sequences. HMG box is highly conserved sequences which has DNA binding and DNA bending activities. It binds to the minor groove of DNA and bent it nearby 60-85° bend [16][17] [18]. Excluding HMG box, sequences present on C-terminus and N- terminus region of *SRY* are poorly conserved within the species and among the species. Although this sequences does not have any clear role in sex determination, several mutations in CTD (C-Terminal Domain) and NTD (N-terminal Domain) leads to DSD [3] [6]. Furthermore, Transcriptional regulation is a function of HMG box [19]. The 20% of XY sex reversal is due to mutations in *SRY* gene. Previous studies illustrate that X chromosome based *SOX* gene is a source of evolution for *SRY* gene. The HMG box sequences of *SOX* gene is very much similar to that of *SRY* which conclude that *SRY* gene was originated from ancestral *SOX* gene [20]. In almost all mammals (except platypus and echidna), *SRY* is a master gene which regulates sex determination. It is a male switch gene because adequate expression of *SRY* decides the sex of the fetus. The studies on mouse implied that difference in *SRY* expression leads to different level of DSD in mouse and human [21]. In combination with other genes, *SRY* regulates the whole mechanism and these genes

are called as “*SRY* and Friend genes”. The *WT1*, *SOX*, *SF1* and several other genes are associated in sex determination.

Mechanism of *SRY* regulation

Regulation of *SRY* starts at intermediate mesoderm, where the first gene *WT1* initiates the path of sex determination. As we discussed in previous section +KTS of *WT1* can directly binds to promoter sequences of *SRY* gene and increase the expression level of *SRY* during male sex determination or male gonad formation [22] [23]. In second step *GATA4* (GATA binding protein 4) and its co factors like *GATA2* (previously called as *FOG2*) involves in sex determination. Normal differentiation of sertoli cells are regulated by *GATA4* and co factors, which indirectly regulates expression of *SRY* gene [17]. Recently it is clearly known that mutant co factor *FOG2* cannot binds to *GATA4*. This results in male gonadal dysgenesis and fails to determine specific sex [24]. Another gene *CBX2*(chromobox 2) directly influences *SRY* expression. Loss of function studies on *SRY* gene in mice implies that decreased *CBX2* results in male to female sex reversal [25]. At this stage urogenital ridge is formed from intermediate mesoderm. From urinogenital ridge to bipotential gonad, several other target genes of *SRY* direct sex determination.




Fig 3: mechanism of *SRY* regulation and involvement of other genes in sex determination and differentiation

During mammalian sex determination, *SOX9*(SOX-box 9) is a direct target gene. It is a best candidate gene in sex determination, second after *SRY* gene. In bipotential gonad, *SOX9* is unregulated in sertoli cell precursors leads to sertoli cell differentiation, immediate after *SRY*

expressed. Functionally down regulated *SOX9* causes autosomal sex reversal [26]. *SOX9* is too involves in several skeletal malformations such as campomelic dysplasia [27] [28]. *TESCO*, testis specific enhancer of *SOX9* core elements are 1.4kb region which is located 11-13kb upstream to *SOX9* and is highly conserved in mammalian gonads [17]. Three putative binding sites present on *TESCO* allow binding *SF1* to *TESCO* which regulates normal expression of *SOX9* in bipotential gonad. This *TESCO-SF1* complex binds to *SRY* resulting to increase or up regulated *SOX9* expression in male gonad [23]. Several previous studies indicated that during the differentiation of sertoli cells, fibroblast growth factor 9, *FGF9* interferes with *SOX9* expression leads to male to female sex reversal. Hence it is important that *SOX9* is up regulated in male and down regulated in female.

SOX 9 (SRY-box 9)

SOX9 is a candidate gene involve in sex determination pathway. Possibly it is a target site for *SRY* action. It belongs to *SOX* family, named *SRY* related HMG box. *SOX9* is located on long q arm of chromosome no.17, mapped 17q24.3-17q25.1 [29]. Initially, *SOX9* is expressed in bipotential genital ridge on lateral side and regulated in sertoli cells, immediately after the expression of *SRY* [3]. *SRY* like HMG domains are encoded by 509 amino acids polypeptide chain which helps *SOX9* to bind with *SRY* [30]. *SOX9* is a universal transcriptional factor which is due to presence of HMG-domain and helps *SRY* to bind and bend DNA [3] [27]. The loss or gain functional studies indicate that mutations of *SOX9* involve in male to female sex reversal [31]. Several mutations like deletion, duplication and translocation in sequences of *SOX9* HMG domain are causes of male to female sex reversal. Studies indicated that beside conserved HMG-Domain, several mutations in ORF (open reading frame) of *SOX9* gene is also involve in sex reversal or gonadal failure [27] [30] [32] [33]. Sequences 193bp far from the starting transcriptional domain, is candidate target domain involve majorly in sex determination pathway, however the mechanism is still unknown. In vitro studies on mice model [34] suggest that induced expression of *SOX9* in XX gonad is sufficient to activate *SRY*, leads to testis development in XX mice gonad [28]. Hence it conforms *SOX9* is essential for *SRY* expression.

Table no.2: several common pathogenic mutations reported in genes responsible for sex determination and differentiation (the data was derived from the ClinVar database of NCBI).

Gene	Mutations	Phenotype
SRY	c.397C>T , c.380A>T, c.337G>A, c.331C>T, c.326T>C , c.324delA c.320G>A, c.317A>T , c.284G>A, c.283G>C, c.277C>T , c.274A>T c.209G>A, c.203T>C , c.192G>A, c.178G>C, c.53G>A, c.12T>A, c.4C>T c.364_367delGAGA,	46,XY sex reversal, type 1
	c.270C>G	46,XY sex reversal, type1, True hermaphrodite
SOX3	21-BP DUP 33-BP DUP	Panhypopituitarism X-linked Isolated growth hormones deficiency
SOX9	136-KB DEL, 577-KB DEL, 240-KB DEL	46,XY sex reversal 1
	148-KB DUP, 96-KB TRIPLICATION, 178-KB DUP,	46,XX sex reversal 2
	1-BP INS, 1103A 1-BP DEL, 296G 1-BP INS, 783G 4-BP INS, c.472G>A c.736dupC, c.1320C>G	Campomelic dysplasia with autosomal sex reversal
	583C-T, c.227C>A, 30-BP DEL, c.462C>G, c.493C>T c.507C>G, c.509C>T c.517A>G, c.1249C>T c.1320C>A	Camptomelic dysplasia No specified phenotype in DSD

	c.442G>T,c.522C>G, c.555delG, c.738delG c.1180C>T, c.1262_1278del17	
RSP01	(IVS5DS, G-A, +1) EX4 DEL, (1-BP INS, 896G)	true hermaphroditism 46,XX sex reversal
WT1	c.787+15T>A, c.1432+4C>T, c.1378T>C c.1432+5G>A, c.1391A>G, c.1390G>A, c.1385G>C, c.1333C>T, c.1323C>G, c.1301G>A, c.1288C>T, c.1282T>G, c.1193G>A c.1384C>T, c.1372C>T,	Frasier syndrome Drash syndrome Frasier syndrome, Drash syndrome
NR0B1	DUP in NR0B1 2.2-KB DEL/27-BP INS, (1-BP INS, 430G) 1-BP DEL, 501A, (4-BP DEL, NT1464) (2-BP DEL, 388AG), (1-BP DEL, 1169C) 2-BP DEL, 1610AG, AND 1-BP INS 1-BP DEL, c.1319A>T, c.1316T>G, c.1274G>T, c.1197C>A, c.1183C>T, c.1146G>T, c.1142T>A, c.1138T>G, c.1107G>A, c.890T>C, c.873G>C, c.847C>T, c.813C>G, c.800G>C, c.788T>A, c.704G>A, c.591C>A,	46,XY sex reversal Congenital adrenal hypoplasia

Disorders of sex development

DSD is gender related disorders or it is related to sex. But 'sex' and 'gender' have different definitions and characteristic; biologically determined are 'sex' whereas socially created male or female characteristic are 'gender'. Congenital conditions in which development of chromosome, gonads or physical sexual characters is abnormal, called as DSD [35]. In 2006, International Consensus Conference on Intersex replaced the term 'inter sex' with DSD (Disorders of Sex development) [36]. Studies indicated that DSD involves vast majorities of Disorders. Some DSDs

are due to gene mutations and others are because of chromosomal imbalance. Turner syndrome (45 XO) [37] [38] [39], Klinefelter syndrome (47 XXY) [39] [40] [41] and chimeric (46 XX/ 46 XY) [42], DSDs are caused by chromosomal imbalance whereas Frasier syndrome [43] [44], Denys–Drash syndrome [45] [46] [47] with Wilms’ tumor [46], congenital adrenal hyperplasia [48] [49] [50] and androgen insensitivity [51] [52] [53] are caused by mutations in autosomal or sex genes. Several other DSDs which are very rare are partial or complete hermaphroditism [54], ovotesticular [42] and ablasio penis [21](micro penis).

Numerical chromosomal DSD

Turner Syndrome (TS)

In 1938, Turner described a group of anomalies with short stature. Later on streak gonads was observed in this particular group of individuals which is called as Turner Syndrome. It is observed in 1 out of 2500 individual with female karyotype [38] and is a most common type of euploidy. 45 XO karyotype was first observed by Ford et al., in 1959 [55]. TS are not inherited. It is arising due to error in cell division; a process called non-disjunction is results in abnormal numbers of chromosome [56]. Clinical sign includes lymphedema of hands and feet, webbed neck, short stature, gonadal dysgenesis, primary amenorrhea, infertility, shield chest and cardiac-renal anomalies are most commonly reported [57]. Some females with TS born with heart defect which is life threatening. Genetically TS is a monosomy in which one X chromosome is absent or altered. Approximately 50% to 60% females [58] with TS does not have one X chromosome and the remaining TS have altered X chromosome as like dicentric, deletion of short arm or ring chromosome. In some cases mosaic X chromosome is reported which is known as mosaic TS. Genital ambiguities are frequent in females with TS. The ovarian failure at early age and infertility is common among turner syndrome [38].

Klinefelter syndrome (KS)

Klinefelter syndrome is a condition in which one extra X chromosome is observed in males and this condition is first reported by Harry Klinefelter in 1942. The rarest condition in this group is 49/XXXXY and, are the group of klinefelter syndrome [40]. KS is occurred in 500 to 1000 in 1 newborn. However, 49/XXXXY is rarest among this [41][59]. KS is originated due to error in cell division in germ cells and nondisjunction of chromosome. Hence KS is not inherited as like other genetic condition [59]. Small testis or testicular failure is common clinical sign. Other characteristics are low testosterone level, eunuchoidism, azoospermia, reduced facial and body hair, gynecomastia, breast enlargement, hypospadias and micro penis [40] [59]. Chances of breast cancer and developmental disabilities are high in this group of individuals. Speech and language problems are mildly observed [59].

Structural chromosomal abnormality

Del(Yp), Del(Yq), Dic(Yp), r(Y), mar(Y), iY(p10), r(X) and mar(X) are common structural abnormalities. Gonadoblastoma, azoospermia, infertility and streak gonads are commonly observed phenotypes of structural rearrangement [60].

Other chromosomal abnormality**Sex reversal**

When visible sex or phenotypic sex does not correlate with the observed sex is called as sex reversal [6]. In simple words, XX males are phenotypically male (physically looks like male) but genotypically female. It is a condition in which a phenotypically normal male has a female genotype [55]. This condition is called as testicular DSD and was first reported by *la cheppele* in 1964. It is a type of rare genetic condition with a frequency of 1:25,000 male new born [61]. During the process of meiosis, several *TDF* gene regions transfer to X chromosome through illegitimate recombination between X and Y chromosome. This process is responsible for XX sex reversal. The pseudoautosomal regions (PAR1 and PAR2) are short regions of homology between the mammalian X and Y chromosomes. The PAR behaves like an autosome and recombined during meiosis. Thus genes in this region are inherited in an autosomal rather than a strictly sex-linked fashion. Some of genes of *TDF* and *SRY* region are also crossover with PAR that causes sex reversal [6]. Several parts of *SRY* gene or complete *SRY* gene is translocates on X chromosome [62]. Patient with 46 XX sex reversal +*SRY* has completely normal male external genitalia but they are azoospermic [55]. Several cases of sex reversal with –*SRY* was also observed. Absence of *SRY* in XX sex reversal leads to abnormal testis development and partial hermaphrodites [61][63]. The reason for sex reversal is Y bearing DNA fragment were present in all cases. In contrast, Ucan et al., 2013 reported that in 2 cases during recombination, had same DNA fragment and one case had different DNA fragment transferred from Y containing DNA of *TDF* [64]. Similar study was performed by Wu et al., (2014) on 5 unrelated male patients. Although external genitalia were normal, *SRY* gene region was present on the tip of Xp. FSH/LH level was high with respect to low testosterone level. Testis had developed normally but *AZF* fragments were not present on *SRY* gene so the patient was found sterile. However, 46 XX sex reversal could not only be influenced by *SRY*, several other genes which are involved in gonadal differentiation such as *SOX9*, *DAX1*, *WT1*, *WANT4* and *RSPO1* were found responsible [22]. Therefore, sex determination in XX males depends on amount of X chromosome inactivation and amount of Y chromosome which is transferred to X.

Table 3: major genes involve in sex determination and it's association with DSD

Sr.no.	Gene name	Type of DSD	Reference
1	<i>WT1</i>	Frasier syndrome, Denys–Drash syndrome with Wilms' tumor	(65)(10)
2	<i>SF1</i>	Gonadal and adrenal dysgenesis	(66)(67)
3	<i>SOX9</i>	Campomelic dysplasia, male gonadal dysgenesis or XY sex reversal	(68)(26)(69)
4	<i>DAX1</i>	Gonadal dysgenesis, congenital adrenal hypoplasia	(70)
5	<i>SRY</i>	Gonadal dysgenesis	(71)(72)(69)
6	<i>GATA4</i>	Ambiguous external genitalia	(73)
7	<i>WNT4</i>	Ambiguous genitalia	(74)(75)
8	<i>RSP01</i>	complete XX sex reversal	(76)(69)

Molecular gene mutation in DSD

Frasier syndrome

George Fraser described this condition in 1962. Phenotypic conditions are same as Denys-Drash syndrome [44]. Abnormalities of ear, nose, syndactyly with abnormal genital profile are common in most cases. Mutations in *WT1* gene are responsible for Frasier condition [43].

Denys-Drash syndrome

Syndromic condition associated with ambiguous genitalia is called as Denys- Drash syndrome [46]. Rarely 150 cases reported world wide till date. The syndrome is associated with ambiguous external genitalia. However most males are normal but ambiguity is observed in females [77]. Within a few months after birth, kidney disease is observed; Glomerulosclerosis is also common [47]. Preliminary, Nephropathy is observed that leads to renal failure. Wilm's tumor is also associated in some of rare conditions [78]. Individual with Denys-Drash syndrome remains infertile. In almost all cases pathogenic mutations are inherited in autosomal dominant manner [47]. Transcriptional factor *WT1* is involved in development of kidney and gonads [10]. As reported earlier, *WT1* plays an important role in genital development. Hence mutation in *WT1* gene affects the activity of other genes (*SRY*, *SOX9* and *NR0B1*) that accelerates abnormal genitalia and renal failure.

Congenital Adrenal Hyperplasia

Adrenal insufficiency leads to CAH in which adrenal gland fails to produce vital hormones for development [49]. Aberrant level of testosterone and androgen leads to abnormal external genitalia.

CAH is recessive condition [79] which occurs 1 in 10,000 to 1 in 20,000 worldwide [48]. Aberrant sex hormones, under developed reproductive tissue, cryptorchidism and infertility are usually observed. *CYP21A2* gene is responsible for classical type of CAH in which aberrant characters notable in female as well [48]. In contrast *NROB1* gene involve in congenital X-linked adrenal hyperplasia [9]. *NROB1* gene is located on X chromosome and important factor during sex determination. Mutation in *NROB1* results in abnormal *DAX1* protein production and that impaired the process of sex development [8].

Androgen insensitivity syndrome

During AIS body is unable to respond to sex hormones androgens. In case of complete androgen insensitivity syndrome, true hermaphrodite (both male and female phenotype) condition is notable [53]. It may occur 1 in 99,000 genetic male individuals [52]. Androgen receptor (*AR*) gene is located on X chromosome and inherited as autosomal recessive condition [52]. Androgen Receptor gene encodes a protein which helps cells to recognize androgen hormones. Mutations in *AR* gene result in low level of testosterone [51]. Hence male sexual characters are endured under-developed. Depending upon the level of androgens, individual became ovotesticular to partial hermaphrodite or true hermaphrodite.

Campomelic dysplasia

Campomelic dysplasia, affects the growth and development of skeleton and reproductive system [80]. Mutations in *SOX9* influence the developmental process during sex determination. The faulty protein formed, is inadequate to normal development. As previously reported, *SOX9* have major role in *SRY* mechanism which ultimately decides the sex of fetus [31]. Hence any mutation in *SOX9* gene eventually causes DSD. It is prevalent 1 in 200000 with autosomal dominant inheritance pattern [80]. Affected fetus born with club feet and long abnormal legs, Curved bones, dislocated hips, abnormal neck and shoulder bones are commonly observed [81] [82]. Prevalence of CD is still uncertain.

2. CONCLUSION

Precisely *SRY* and related genes are responsible for DSD. However genetic basis of eunuchism is still unknown. Definite physical examinations are proven that in most cases eunuchs have abnormal external genitalia and which is due to mutations in several genes, during early developmental stage. Social status of hijras remains controversial in India. So the genetic studies are restricted. Eunuchs (Hijras) are intersex but still their intersex status is not defined due to lack of research

CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

1. Sindhe ujwala sunil. Gender justice and status of eunuch. *Int J Humanit Soc Sci Invent.* 2012;1(1):1–6.
2. Sharma P. Historical Background and Legal Status of Third Gender in Indian Society. *IJRESS.* 2012;2(12):64–71.
3. She Z, Yang WX. Molecular mechanisms involved in mammalian primary sex determination. *J Mol Endocrinol.* 2014;53(1):R21–37.
4. HUGHES IA. Minireview : Sex Differentiation. *Endocrinology.* 2001;142(8):3281–7.
5. Rey R, Josso N. *Sexual Differentiation The Bipotential Gonad.* 2013.
6. Wilhelm D, Palmer S, Koopman P. Sex determination and gonadal development in mammals. *Physiol Rev.* 2007;87(1):1–28.
7. Morel Y, Roucher F, Mallet D, Plotton I. Genetic of gonadal determination. *Ann Endocrinol (Paris).* 2014;75(2):32–9.
8. Barbaro M, Balsamo A, Anderlid BM, Myhre AG, Gennari M, Nicoletti A, et al. Characterization of deletions at 9p affecting the candidate regions for sex reversal and deletion 9p syndrome by MLPA. *Eur J Hum Genet. Nature Publishing Group;* 2009;17(11):1439–47.
9. Larson A, Nokoff NJ, Travers S. Disorders of Sex Development: Clinically Relevant Genes Involved in Gonadal Differentiation. *Discov Med.* 2012;14(78):301–9.
10. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, et al. Two splice variants of the wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. *Cell.* 2001;106(3):319–29.
11. Pandian TJ. Lability of sex differentiation in fish. *Curr Sci.* 1999;76(4):580–3.
12. Sadovsky Y, Dorn C. Function of steroidogenic factor 1 during development and differentiation of the reproductive system. *Rev Reprod.* 2000;5(3):136–42.
13. Graves J a M. Evolution of the testis-determining gene--the rise and fall of SRY. *Novartis Found Symp* 2002;244(February 2002):86–97.
14. Drobnič K. A new primer set in a SRY gene for sex identification. *Int Congr Ser.* 2006;1288:268–70.
15. Koopman P, Sinclair A, Lovell-Badge R. sex and determination: marking 25 years of Randy, the sex-reversed mouse. *Development.* 2016;143(10):1633–7.
16. Ono M, Harley VR. Disorders of sex development: new genes, new concepts. *Nat Rev Endocrinol. Nature Publishing Group;* 2013;9(2):79–91.
17. Hacker A, Capel B, Goodfellow P, Lovellbadge R. Expression of sry, the mouse sex-determining gene. *Development.* 1995;121(6):1603–14.
18. Bowles J, Koopman P. New clues to the puzzle of mammalian sex determination. *Genome Biol.* 2001;2(9).

19. Correa R V., Domenice S, Bingham NC, Billerbeck AEC, Rainey WE, Parker KL, et al. A microdeletion in the ligand binding domain of human steroidogenic factor 1 causes XY sex reversal without adrenal insufficiency. *J Clin Endocrinol Metab.* 2004;89(4):1767–72.
20. Forger NG, Rosen GJ, Waters EM, Jacob D, Simerly RB, de Vries GJ. Deletion of Bax eliminates sex differences in the mouse forebrain. *Proc Natl Acad Sci.* 2004;101(37):13666–71.
21. Migeon CJ, Wisniewski AB. Sexual differentiation: From genes to gender. *Horm Res.* 1998;50(5):245–51.
22. Wu Q, Li N, Li W, Li T, Zhang C, Cui Y, et al. Clinical , molecular and cytogenetic analysis of 46 , XX testicular disorder of sex development with SRY -positive. 2014;1–5.
23. Li T-F, Wu Q-Y, Zhang C, Li W-W, Zhou Q, Jiang W-J, et al. 46,XX testicular disorder of sexual development with SRY-negative caused by some unidentified mechanisms: a case report and review of the literature. *BMC Urol.* 2014;14:104.
24. Lourenço D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, et al. Mutations in NR5A1 associated with ovarian insufficiency. *N Engl J Med.* 2009;360(12):1200–10.
25. Biason-Lauber, Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. *Am J Hum Genet.* 2000;67(6):1563–8.
26. Lamb A, Huang B, Wang S, Ning Y, Lamb AN, Bartley J. Autosomal XX sex reversal caused by duplication of SOX9. *Am J Med Genet.* 2000;87:349–53.
27. Kwok C, Weller PA, Guioli S, Foster JW, Mansour S, Zuffardi O, et al. Mutations in SOX9 , the Gene Responsible for Campomelic Dysplasia and Autosomal Sex Reversal. *Am J Hum Genet.* 1995;57:1028–36.
28. Parma P, Radi O, Vidal V, Chaboissier MC, Dellambra E, Valentini S, et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. *Nat Genet.* 2006;38(11):1304–9.
29. Henry KP, Harley V, Henry P. Turning on the male - SRY , SOX9 and sex determination in mammals. *Cytogenet Genome Res.* 2003;(101):185–98.
30. Mcdowall S, Argentaro A, Mcdowall S, Argentaro A, Ranganathan S, Weller P, et al. Functional and Structural Studies of Wild Type SOX9 and Mutations Causing Campomelic Dysplasia. *J Biol Chem.* 1999;274(34):24023–30.
31. Lamb A, Huang B, Wang S, Ning Y, Lamb AN, Bartley J. Autosomal XX sex reversal caused by duplication of SOX9. *Am jouranl Med Genet.* 1999;87(August):349–53.
32. Knower KC, Kelly S, Harley VR. Turning on the male - SRY, SOX9 and sex determination in mammals. *Cytogenet Genome Res.* 2003;101(3-4):185–98.
33. Shaw MA, Haines B, Hughes J, Corbett M, Shaw M, Innes J, et al. Interchromosomal

- Insertional translocation at Xq26.3 alters SOX3 expression in an individual with XX male sex reversal. *J Clin Endocrinol Metab.* 2015;100(5):E815–20.
34. Kanai Y, Koopman P. Structural and functional characterization of the mouse Sox9 promoter : implications for campomelic dysplasia. *Hum Mol Genet.* 1999;8(4):691–3.
 35. Mendonca BB, Domenice S, Arnhold IJP, Costa EMF. 46,XY disorders of sex development (DSD). *Clinical Endocrinology.* 2009. 173-187.
 36. I A Hughes, C Houk, S F Ahmed, P A Lee. Consensus statement on management of intersex disorders. *Arch Dis Child.* 2006;7(91):554–63.
 37. I LPE, Dourado A, Iv G, V BB. Y chromosome in Turner syndrome : review of the literature. *Sao Paulo Med J*2009. 2009;127(6):373–8.
 38. Bernadete A, Marqui T De. Turner syndrome and genetic polymorphism : a systematic review. *Rev Paul Pediatr.* 2015;33(3):363–70.
 39. Sybert VP, Mccauley E. Turner’s Syndrome. *N Engl J Med.* 2004;351:1227–38.
 40. Visootsak J, Graham JJM. Klinefelter syndrome and other sex chromosomal aneuploidies. *orphanet J rare Dis.* 2006;1(42):1–5.
 41. Nieschlag E. Klinefelter Syndrome. *Dtsch Arztebl Int.* 2013;110(20):347–54.
 42. Macías-gómez NM, Leal-ugarte E, Gutiérrez-angulo M, Domínguez-quezada G, Rivera H, Barros-núñez P. 46 , XX ovotesticular disorder in a Mexican patient with Beckwith – Wiedemann syndrome : a case report. *J Med case Rep.* 2012;301(6):4–7.
 43. Guaragna MS, Cristina A, Britto G De, Bittencourt B, Santos C, Piveta C, et al. Frasier syndrome: four new cases with unusual presentations. *Arq Bras Endocrinol Metab.* 2012;56(8):525–32.
 44. Peco-antić A, Ozaltin F, Parezanović V, Miloševski-lomić G. Proteinuria in Frasier Syndrome. *Srp Arh Celok lek.* 2013;141(9-10):685–8.
 45. Kucinkas L, Just W. Denys- Drash syndrome. *Med Kaunas.* 2005;41(2):132–4.
 46. Kabra M, Kataria A. Denys-Drash Syndrome. *Indian Pediatr.* 1995;32:1310–3.
 47. Niaudet P. Denys-Drash syndrome. *Orphanet.* 2004;(October 2001):1–3.
 48. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency : An Endocrine Society Clinical Practice Guideline Morbidities of Congenital Adrenal. *J clin Endocrinol Metab.* 2010;95(August):4133–60.
 49. Speiser PW. Congenital Adrenal Hyperplasia. *F1000 Res.* 2015;601:1–4.
 50. Speiser P, Speiser PW. Congenital Adrenal Hyperplasia. Referee Status : 2016
 51. Galani A, Kitsiou-tzeli S, Sofokleous C, Kanavakis E, Kalpini-mavrou A. Androgen insensitivity syndrome : clinical features and molecular defects. *Hormones.* 2008;7(3):217–29.
 52. Oakes MB, Eyvazzadeh AD, Quint E, Smith YR. Mini-Reviews Complete Androgen

- Insensitivity Syndrome — A Review. *J Pediatr Adolesc Gynecol*. Elsevier Inc; 2008;21(6):305–10.
53. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, Macdougall J. Androgen insensitivity syndrome. *Lancet*. Elsevier Ltd; 2012;380:1419–28.
54. Jaubert F, Josso N, Fellous M. Hermaphroditism pathology. *Morphol-Embryol*, 2004;XLV:41–51.
55. de la Chapelle A. Analytic review: nature and origin of males with XX sex chromosomes. *Am J Hum Genet*. 1972;24(1):71–105.
56. Zhong Q, Layman LC. Genetic considerations in the Patient with Turner Syndrome 45, X with or without Mosaicism. *Fertil Steril*. 2012;98(4):775–9.
57. Gonzalez L, Witchel SF. The Patient with Turner Syndrome: Puberty and Medical Management Concerns. *Fertil Steril*. 2012;98(4):780–6.
58. Kulkarni KP, Panigrahi I, Das R, Kaur S, Marwaha RK. Pediatric disorders of sex development. *Indian J Pediatr*. 2006;76:956–8.
59. Amory JK, Anawalt BD, Paulsen CA, Bremner WJ. Klinefelter's syndrome. *Lancet*. 2000;356:333–5.
60. Shabsovich D, Tirado CA. Genes , Chromosomes , and Disorders of Sex Development : An Update. *J Assoc Genet Technol*. 2014;40(3):124–30.
61. Rajender S, Rajani V, Gupta NJ, Chakravarty B, Singh L, Thangaraj K. SRY-negative 46,XX male with normal genitals, complete masculinization and infertility. *Mol Hum Reprod*. 2006;12(5):341–6.
62. Alves C, Braid Z, Coeli FB, Mello MP De. 46,XX male - testicular disorder of sexual differentiation (DSD): hormonal, molecular and cytogenetic studies. *Arq Bras Endocrinol Metabol*. 2010;54(8):685–9.
63. Abusheikha N, Lass a, Brinsden P. XX males without SRY gene and with infertility. *Hum Reprod*. 2001;16(4):717–8.
64. Uçan B, Özbek M, Topaloğlu O, Yeşilyurt A, Güngüneş A, Demirci T, et al. 46,XX Male Syndrome. *Turkish J Endocrinol Metab*. 2013;17(2):46–8.
65. Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, et al. The Wilms tumor gene , *Wt1* , is required for *Sox9* expression and maintenance of tubular architecture. *PNAS*. 2006;103(32):11987–92.
66. Park SY, Meeks JJ, Raverot G, Pfaff LE, Weiss J, Hammer GD, et al. Nuclear receptors *Sf1* and *Dax1* function cooperatively to mediate somatic cell differentiation during testis development. *Dev Dis*. 2005;132:2415–23.
67. Lin L, Philibert P, Ferraz-de-souza B, Kelberman D, Homfray T, Molini V, et al. UKPMC Funders Group Author Manuscript Ad4BP , NR5A1) are associated with 46 , XY disorders of

- sex development with normal adrenal function. 2007;92(3):991–9.
68. Barrionuevo F, Bagheri-fam S, Kist R, Taketo MM, Englert C, Scherer G. Homozygous Inactivation of Sox9 Causes Complete XY Sex Reversal in Mice 1. *Biol Reprod.* 2006;74(October 2005):195–201.
69. Camerino G, Parma P, Radi O, Valentini S. Sex determination and sex reversal. *Curr Opin Genet Dev.* 2006;16(3):289–92.
70. Meeks JJ, Crawford SE, Russell TA, Morohashi K, Weiss J, Jameson JL. Dax1 regulates testis cord organization during gonadal differentiation. *Development.* 2003;130:1029–36.
71. Amudha S, Rajangam S, Thangaraj K, Mahalingam K. SRY (sex determining regions in Y) basis of sex reversal in XY females. *Int J Hum Genet.* 2012;12(2):99–103.
72. Polanco JC, Koopman P. Sry and the hesitant beginnings of male development. *Dev Biol.* 2007;302(1):13–24.
73. Hu Y, Okumura LM, Page DC. Gata4 Is Required for Formation of the Genital Ridge in Mice. *PLOS Genet.* 2013;9(7):1–12.
74. Jordan BK, Shen JH, Olaso R, Ingraham HA, Vilain E. Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing steroidogenic factor beta-catenin synergy. *PNAS Genet.* 2003;100(19):10866–71.
75. Yao HHC, Matzuk MM, Jorgez CJ, Menke DB, David C, Swain A, et al. Follistatin Operates downstream of WNT4 in mammalian ovary organogenesis. *Dev Dyn.* 2014;230(2):210–5.
76. Chassot AA, Ranc F, Gregoire EP, Roepers-Gajadien HL, Taketo MM, Camerino G, et al. Activation of beta-catenin signaling by Rspo1 controls differentiation of the mammalian ovary. *Hum Mol Genet.* 2008;17(9):1264–77.
77. Mueller RF. The Denys-Drash syndrome. *J Med Genet.* 1994;31:471–7.
78. Heathcott RW, Morison IM, Gubler MC, Corbett R, Reeve AE. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X. *Hum Mutat.* 2002;19(4):462.
79. White PC, Bachega TASS. Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency : From Birth to Adulthood. *Semin Reprod Med.* 2012;30:400–9.
80. Karaer K, Yüksel Z, Yalınbaş E, Scherer G. Case Report A case of campomelic dysplasia in whom a new mutation was found in the SOX9 gene. *turkish Arch Pediatr.* 2014;49:154–6.
81. Gimovsky M, Rosa E, Tolbert T, Guzman G, Nazir M, Koscica K. Campomelic Dysplasia: case report and review. *J Perinatol.* 2008;28:71–3.
82. Mattos EP, Sanseverino MT V, Magalhães JAA, Leite JCL, Félix TM, Todeschini LA, et al. Clinical and molecular characterization of a Brazilian cohort of campomelic dysplasia patients and identification of seven new SOX9 mutations. *Genet Mol Biol.* 2015;38:14–20.